Subscribe To
Inozyme pharma to present at the jefferies healthcare conference
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing
June 2, 2023, 7:30 am
Plant disease diagnostics market is estimated to surge ahead at a cagr of 4.1% to reach us$ 150.6 million by the end of 2033, persistence market research
Growing Global Demand for Infectious Disease Diagnostics is Paving Way for novel Methods of Detection f...
June 1, 2023, 1:40 pm
Zymeworks announces participation in upcoming investor conferences
VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel...
June 1, 2023, 12:30 pm
Madrigal pharmaceuticals announces participation at two upcoming investor conferences
CONSHOHOCKEN, Pa., June 01, 2023 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursui...
June 1, 2023, 12:00 pm
Zymeworks announces participation in upcoming investor conferences
VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel,...
June 1, 2023, 8:30 am
Tyra biosciences: early stage developer of novel fgfr3-selective molecules
TYRA has the first FGFR3 inhibitor in the clinic. The company has a large market cap for an early-stage company and a good deal of cash. They do not h...
June 1, 2023, 5:25 am
Oncternal therapeutics to participate at the 2023 jefferies healthcare conference
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the de...
May 31, 2023, 9:00 pm
Landos biopharma to present at the 2023 jefferies healthcare conference
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral m...
May 31, 2023, 8:15 pm
Sanofi (sny) nextgen multiple sclerosis drug meets phase ii goal
Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the p...
May 31, 2023, 1:16 pm
Arbutus to present at jefferies healthcare conference
WARMINSTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage...
May 31, 2023, 11:30 am
Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...
May 31, 2023, 3:00 am
Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...
May 31, 2023, 3:00 am
Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...
May 31, 2023, 3:00 am
Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...
May 31, 2023, 3:00 am
Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...
May 31, 2023, 3:00 am
Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...
May 31, 2023, 3:00 am
Biomx to present part 1 data from phase 1b/2a study evaluating bx004 for the treatment of chronic pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during late-breaking scie
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clini...
May 31, 2023, 3:00 am
Belite bio announces pricing of $30 million underwritten public offering of american depositary shares and warrants
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical stage biopharmaceutica...
May 31, 2023, 12:49 am
The blister packaging market is projected to reach a valuation of us$ 26,940.0 million by 2033, at a cagr of 6.8% | future market insights, inc.
The Blister Packaging Market is Going to Expand as a Result of Growing Demand for Pharmaceutical Tablets and the Development of ...
May 31, 2023, 12:30 am
Got beef? consumers increasingly don't
Q1 earnings calls featured a decent dose of negative commentary on consumers and the economy and one novel ...
May 30, 2023, 5:19 pm